IL6 and acute respiratory distress syndrome: Studies undertaken with n-3 PUFAs containing parenteral lipid emulsions in patients undergoing major abdominal surgery[10, 11], in patients undergoing surgery for aortic aneurism repair[12], and in patients with acute respiratory distress syndrome (ARDS)[13, 14], have proven clinically to reduce length of post-operative hospital stay, frequency of post-operative complications, as well as to lower the levels of pro-inflammatory factors such as leukotriene B4 (LTB4)[14] and Interleukin 6 (IL-6)[15].